[Media Releases] 2011 ICAAC, Renewed Optimism over Antimicrobial Prospects (MicrobeMagazine, Dec 2011)
Title: 2011 ICAAC, Renewed Optimism over Antimicrobial Prospects Publication: Micro Magazine Date: December 2011 URL: link to website
Several newly developed cyclic amidrazone or amidoxime derivatives of oxazolidinone display activity against linezolid-resistant gram- positive pathogens, according to Yong-Zu Kim of LegoChem Biosciences in Daejeon, South Korea. With linezolid still the only oxazolidinone approved for human use, he says, 'we are continuing to optimize our lead compound and to support further development for use against gram-positive pathogens.'
About LegoChem Biosciences
LegoChem Biosciences, Inc. (LCB) is a research-based biotechnology company dedicated to discovering, developing, and commercializing innovative medicines by leveraging our chemistry expertise to make conventional biologics targeted and more potent for the benefit of patients with diseases of high unmet medical needs. We are advancing sustainable pipelines in therapeutic areas in antibiotics, anti-coagulants, oncology, antibody-drug conjugate (ADC), and protein-drug conjugate (PDC). |